Ali Behbahani, M.D., M.B.A., has served on our Board of Directors since April 2015. He is a Partner and Co-Head of the Healthcare team at New Enterprise Associates, Inc. (NEA), where he has worked since 2007.
Dr. Behbahani brings extensive board experience across the biopharmaceutical and biotechnology sectors. He currently serves on the boards of Adaptimmune Therapeutics plc (ADAP) since 2014; Nkarta, Inc. (NKTX) since 2015, and Chairman since 2019; Black Diamond Therapeutics, Inc. (BDTX) since 2018; Monte Rosa Therapeutics, Inc. (GLUE) since 2020; Korro Bio, Inc. (KRRO) since 2019; and Arcellx, Inc. (ACLX) since 2015. His past board roles include CVRx, Inc. (CRVX), Minerva Surgical Inc. (UTRS), Oyster Point Pharma, Inc., and Genocea Biosciences, Inc.
Before joining NEA, he held roles in healthcare investment banking and corporate development, including positions at Lehman Brothers, Morgan Stanley, and The Medicines Company.
Dr. Behbahani earned his M.D. from the University of Pennsylvania School of Medicine and an M.B.A. with honors from the Wharton School, where he was named a Palmer Scholar. He also holds a B.S. in Biomedical Engineering, Electrical Engineering, and Chemistry from Duke University.
What is Ali Behbahani's net worth?
The estimated net worth of Ali Behbahani is at least $807.89 thousand as of September 17th, 2026. Dr. Behbahani owns 16,637 shares of CRISPR Therapeutics stock worth more than $807,893 as of November 6th. This net worth approximation does not reflect any other investments that Dr. Behbahani may own. Learn More about Ali Behbahani's net worth.
How do I contact Ali Behbahani?
Has Ali Behbahani been buying or selling shares of CRISPR Therapeutics?
Ali Behbahani has not been actively trading shares of CRISPR Therapeutics over the course of the past ninety days. Most recently, Ali Behbahani sold 13,679 shares of the business's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $57.09, for a transaction totalling $780,934.11. Following the completion of the sale, the director now directly owns 16,637 shares of the company's stock, valued at $949,806.33. Learn More on Ali Behbahani's trading history.
Who are CRISPR Therapeutics' active insiders?
CRISPR Therapeutics' insider roster includes Ali Behbahani (Director), Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Simeon George (Director), John Greene (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Naimish Patel (Chief Medical Officer), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.
Are insiders buying or selling shares of CRISPR Therapeutics?
In the last year, insiders at the sold shares 19 times. They sold a total of 239,172 shares worth more than $12,836,637.11. The most recent insider tranaction occured on October, 19th when CEO
Samarth Kulkarni sold 47,837 shares worth more than $2,381,325.86. Insiders at CRISPR Therapeutics own 5.2% of the company.
Learn More about insider trades at CRISPR Therapeutics. Information on this page was last updated on 10/19/2026.
